Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 2 November 2021, 16:30 HKT/SGT

Source: JSP Pharmaceutical Manufacturing (Thailand) PCL
JSP Pharmaceutical Manufacturing (SET: JP) debuts shares on MAI
Aims to be leader in R&D, production and distribution of medicines and nutritional supplements

BANGKOK, Nov 2, 2021 - (ACN Newswire) - JSP Pharmaceutical Manufacturing (Thailand) PCL (SET: JP), a developer, manufacturer and distributor of modern and traditional medicines, herbal products and nutritional supplements, is debuting on the MAI today. JSP is ready to pursue growth through developing new products under own brands, aiming for higher profit margins by boosting own brand sales to 50% of total sales of all products, while increasing capacity, improving capital management efficiency, expanding OEM production, and ultimately leading in the R&D, production and distribution of medicines and nutritional supplements.

Dr. Sittichai Daengprasert, Chief Executive Officer of JSP Pharmaceutical Manufacturing (Thailand) PCL, whose shares will begin trading on the SET Market of Alternative Investment (MAI) today in the Consumer Products sector under the symbol JP, says it is a crucial step for the company to pursue sustainable growth in order to become a leader in the R&D, manufacture and distribution of medicinal and nutritional supplement products in Thailand. It plans to drive growth with innovations in the development of modern and traditional medicines, and herbal and nutritional supplement products to satisfy consumers' demand for high-quality products for health maintenance, protection and treatment. The plan will lend support to Thailand's effort to become a society of health care in the near future.

Dr. Sittichai says the proceeds from the IPO share sales will go toward the development of new health products under the company's own brands with a goal to produce 4-5 new products each year. Meanwhile, a multi-channel marketing strategy will be employed for product distribution, encompassing pharmacies, modern trade stores, convenience stores, TV home shopping, and online channels. The aim is to boost sales of own-brand products to 50% of total sales, which will contribute positively to the gross profit in the future.

Plans to improve the efficiency of the Bangkok plant, a hub of modern medicine production, and expand the capacity of the plant in Lamphun, which produces traditional medicines and nutritional supplements, will support the expansion of the OEM customer base in Thailand and in the CLMV countries with a one-stop service. Equipped with a list of more than 2,000 registered medicines, JP is in an advantageous position to meet OEM customers' demands, Dr. Sittichai says.

He adds that the company has also been cooperating with educational institutes, government agencies and private-sector parties in the development and processing of herbs, such as Wolffia globosa, as a plant-based protein supplement under the 'Suphap Osot' brand to add value to agricultural products. In this program, cultivation know-how is transferred to farmers as a way to help them earn increased income. Furthermore, JP is preparing its manufacturing base to produce extracts from cannabis and hemp. These extracts are to be sold as processed products or used as ingredients in health products under the company's own brands.

Mr. Vorachart Tuaychareon, Managing Director of Finnex Advisory Co., Ltd., a financial advisor, says JP's potential for growth looks bright amid positive factors resulting from increasing demands for modern and herbal medicines from health-conscious consumers while the government sector encourages people to consume locally-made medicinal products. The company's extensive experience and expertise in the R&D of diverse medicinal products and its experienced executives' ceaseless pursuit of business opportunities are sure to improve its competitiveness and growth prospects.

Mr. Chosit Detwanitchayanumut, Managing Director of Siam Alpha Capital Co., Ltd., a joint financial advisor, says JP is determined to strengthen its operations in all respects by highlighting product innovations and investing in marketing campaigns to increase public awareness of its own brands as well as expand its OEM customer base both here and abroad. The company's strong fundamentals lend firm support for its drive toward a sustainable growth, he adds.

Mr. Chanachai Joonjiraporn, Chief Executive Officer, ASL Securities Co., Ltd., the lead underwriter, says JP's shares are growth stock because of the strength of its operations. Its commitment to pursue long-term and sustainable growth lays a firm foundation on which its shares are grounded and is the reason that will attract sustained investors' interest in JP's shares.

Released by Public Relations Dept., MT Multimedia Co. Ltd.
for JSP Pharmaceutical Manufacturing (Thailand) PCL
For more information, please contact: Yuttachai Praikhanahok (Tle)
Tel: +66-91-736-2866 or +66-2-612-2081 ext 125

Topic: IPO
Source: JSP Pharmaceutical Manufacturing (Thailand) PCL

Sectors: Daily Finance, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
Pixis (Formerly Pyxis One) Raises $100M in SoftBank Vision Fund 2-led Series C to Grow Its Codeless AI Infrastructure   
Jan 22, 2022 02:00 HKT/SGT
2022's First SPAC and Metaverse Investment Opportunities Virtual Investment Conference in Hong Kong  
Jan 21, 2022 19:35 HKT/SGT
Yeahka ranks No. 1 in the non-bank independent QR code payment service market in China  
Jan 21, 2022 17:51 HKT/SGT
Mitsubishi Power Europe and Stockholm Exergi partner to deliver clean power and heat to the city of Stockholm  
Friday, January 21, 2022 3:51:00 PM
MoU Between Verofax Asia and Distichain to Enable Empowered Digital Global Trade  
Jan 21, 2022 14:00 HKT/SGT
What You Need to Know about TRON in 2022  
Jan 21, 2022 13:00 HKT/SGT
Ingerson Capital Partners Releases the Performance Report on 'Asia Driving Demand for Longer Trading Hours'  
Jan 21, 2022 13:00 HKT/SGT
Realbox launches one of world's first blockchain-based real estate tokenization platforms  
Jan 20, 2022 20:00 HKT/SGT
Slime Royale Announces to Receive Strategic Investment and Incubation Support from Appota Group  
Jan 20, 2022 14:00 HKT/SGT
Hitachi Rail Awarded Contract to Operate and Maintain Princess Noura Bint Abdul Rahman University Autonomous System in Riyadh, Saudi Arabia  
Thursday, January 20, 2022 1:14:00 PM
More Press release >>
More >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: